AIxCrypto Holdings, Inc.
AIXC evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $23.0M
- Lead Asset:
- pan-ras (Preclinical)
What it means
What to watch
Prepared research question
What matters most for AIXC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIXC
AIxCrypto Holdings, Inc. (AIXC) is a technology company pivoting from a three-business-line structure (BesTrade DeAI Agent platform, C10 digital asset tools, and RWA Embodied AI ecosystem) to focus solely on the RWA + Embodied AI (EAI) ecosystem, while also maintaining early-stage therapeutic programs (QN-302 and Pan-RAS) from a prior incarnation as a cancer therapeutics company.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$23.0M
Cash Runway
—
Lead Asset
pan-ras (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for AIxCrypto Holdings, Inc..
AIxCrypto Holdings, Inc. (AIXC) is a technology company pivoting from a three-business-line structure (BesTrade DeAI Agent platform, C10 digital asset tools, and RWA Embodied AI ecosystem) to focus solely on the RWA + Embodied AI (EAI) ecosystem, while also maintaining early-stage therapeutic programs (QN-302 and Pan-RAS) from a prior incarnation as a cancer therapeutics company.
- As of 2026-06-30, AIXC reported cash & equivalents of $0.6M, net income of -$4.2M, shareholders' equity of $5.7M, and total debt of $0.5M [sec].
- In February 2026, the board decided to concentrate on the RWA + Embodied AI (EAI) ecosystem and discontinue development of the BesTrade platform and C10 portfolio management tools [sec · filed 2026-08-18].
- The company has two therapeutic programs: QN-302 (Phase 1, pancreatic cancer, orphan drug) and Pan-RAS (preclinical, pan-ras inhibitor) [pipeline].
- AIXC describes itself as an early-clinical-stage therapeutics company focused on adult and pediatric cancer, but also as a technology company focused on embodied AI commercialization [sec_mda · as of 2025-11-14][sec_mda · as of 2026-08-07].
- The company has no material contractual obligations beyond those recorded on its balance sheets, but has milestone-based payment obligations under license agreements [sec_mda · as of 2026-05-11].
What works
- The company has secured an exclusive worldwide in-license for the Pan-RAS program from the University of Louisville, with royalties in low-to-mid-single-digit percentages on net sales [pipeline].
- QN-302 has received Orphan Drug designation and is in Phase 1 for pancreatic cancer, with an exclusive global in-license from University College London [pipeline].
- The company has no material contractual obligations beyond those disclosed, suggesting a clean balance sheet with respect to undisclosed liabilities [sec_mda · as of 2026-05-11].
What to weigh
- Cash position is very low at $0.6M as of 2026-06-30, with a net loss of $4.2M, indicating a tight financial runway [sec].
- The company discontinued its two earlier business lines (BesTrade and C10) after they failed to meet scale, regulatory, or margin targets, reflecting a strategic reset [sec · filed 2026-08-18].
- Both therapeutic programs are early-stage (preclinical and Phase 1) and face significant development risk, with 97 competitors listed for the Pan-RAS program [pipeline].
- The company acknowledges risks including ability to raise financing, maintain Nasdaq listing, and successfully develop drugs [sec_mda · as of 2026-05-11].
From the filings
Quoted directly from source documents.
Company's strategic pivot to RWA + Embodied AI ecosystem and discontinuation of BesTrade and C10
“In February 2026, the Company's board determined to concentrate on the RWA + Embodied AI (EAI) ecosystem. In connection with that decision, the Company has determined to discontinue development of the BesTrade platform and the C10 portfolio management tools.”
SEC filings · August 18, 2026
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash of $0.6M as of 2026-06-30 may be insufficient to fund operations and development for more than a few months [sec].
- Early-stage pipeline — Both therapeutic programs are preclinical or Phase 1, with high risk of failure and long timelines to revenue [pipeline].
- Strategic pivot execution risk — Discontinuation of two business lines indicates past strategy did not meet targets; new focus on EAI is unproven [sec · filed 2026-08-18].
- Competitive pressure — Pan-RAS faces 97 competitors, including Phase 2/3 programs from established firms [pipeline].
What to watch
- Ability to raise additional financing given low cash and net loss [sec][sec_mda · as of 2026-05-11].
- Progress of QN-302 Phase 1 trial and any regulatory updates for pancreatic cancer [pipeline].
- Execution of the RWA + Embodied AI pivot and any new partnerships or product announcements [sec · filed 2026-08-18].
- Potential milestone payments under license agreements that could become due if development advances [sec_mda · as of 2026-05-11].
Sources: Competitor trials · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run AIxCrypto Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AIxCrypto Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.30 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 0.4%
- Days to cover
- 1.7
- Shares short
- 87,806
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIXC short interestGovernance
Frequently asked questions
What is the AI investment thesis for AIxCrypto Holdings, Inc.?
AIxCrypto Holdings, Inc. (AIXC) is a technology company pivoting from a three-business-line structure (BesTrade DeAI Agent platform, C10 digital asset tools, and RWA Embodied AI ecosystem) to focus solely on the RWA + Embodied AI (EAI) ecosystem, while also maintaining early-stage therapeutic programs (QN-302 and Pan-RAS) from a prior incarnation as a cancer therapeutics company.
What is AIxCrypto Holdings, Inc.'s lead drug candidate?
AIxCrypto Holdings, Inc.'s most advanced tracked candidate is pan-ras (Preclinical) for pancreatic, colorectal and lung cancers.
Who is the CEO of AIxCrypto Holdings, Inc.?
Mr. Jiawei Wang is the chief executive officer of AIxCrypto Holdings, Inc. (AIXC).
Where is AIxCrypto Holdings, Inc. headquartered?
AIxCrypto Holdings, Inc. (AIXC) is headquartered in El Segundo, CA, United States.
What therapeutic areas does AIxCrypto Holdings, Inc. focus on?
AIxCrypto Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.